Galectin Therapeutics (GALT) Projected to Post Earnings on Monday

Galectin Therapeutics (NASDAQ:GALT) is anticipated to announce its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 9:30 AM ET.

Galectin Therapeutics Stock Down 1.8%

Shares of NASDAQ:GALT opened at $2.75 on Monday. Galectin Therapeutics has a fifty-two week low of $1.12 and a fifty-two week high of $7.13. The firm’s 50-day simple moving average is $3.01 and its 200-day simple moving average is $4.32. The company has a market cap of $177.30 million, a price-to-earnings ratio of -4.66 and a beta of 0.98.

Insiders Place Their Bets

In related news, CEO Joel Lewis sold 37,698 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $3.58, for a total value of $134,958.84. Following the completion of the sale, the chief executive officer owned 832,592 shares in the company, valued at $2,980,679.36. This trade represents a 4.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Khurram Jamil sold 21,446 shares of the business’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $3.65, for a total transaction of $78,277.90. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 204,000 shares of company stock worth $787,433. Corporate insiders own 52.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in GALT. XTX Topco Ltd grew its holdings in shares of Galectin Therapeutics by 226.6% in the 2nd quarter. XTX Topco Ltd now owns 42,805 shares of the company’s stock worth $90,000 after acquiring an additional 29,699 shares during the period. Balyasny Asset Management L.P. acquired a new position in Galectin Therapeutics during the fourth quarter worth $90,000. Mangrove Partners IM LLC purchased a new stake in Galectin Therapeutics during the fourth quarter worth $78,000. Russell Investments Group Ltd. boosted its position in Galectin Therapeutics by 9,997.2% during the fourth quarter. Russell Investments Group Ltd. now owns 18,074 shares of the company’s stock worth $75,000 after purchasing an additional 17,895 shares in the last quarter. Finally, Jefferies Financial Group Inc. acquired a new stake in Galectin Therapeutics in the third quarter valued at $73,000. 11.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GALT has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a research report on Thursday, January 22nd. HC Wainwright boosted their target price on Galectin Therapeutics from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Galectin Therapeutics has an average rating of “Hold” and an average price target of $11.00.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.